_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Tafinlar (dabrafenib) in combination with Mekinist (trametinib) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.1,2

Please select treatment of BRAF-positive metastatic melanoma below to find out more; then, consider treatment from a patient perspective by clicking on ‘Management of patients with BRAF positive melanoma’.

References

  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
IE 177162 November 2021

Prescribing information

 

Click here for product API

Reporting of side effects
Adverse events (side effects) can be reported via the HPRA. Reporting forms and information can be found at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling (01) 2080 612. For information on any of our medicinal products please contact Medical Information on (01) 260 1255.

×

Ask Speakers

×

Medical Information Request